Online evolution

Thursday, December 15th, 2011

Earlier this week we unveiled a major update to our online presence with the release of our new-look website and the launch of Mothers & Children, a new site focusing on the pediatric and parental skincare.

Over the past five years the team has worked to continuously improve our online resources, expand into social media and build our presence on our Youtube channel (generating over 100,000 views in the process). The new site, Mothers & Children, is a direct response to what we saw as a key gap in online skincare information: up-to-date, accurate and concise information on caring for and protecting young and maternal skin. This is a new space for us and we’re excited to be able to compliment our extensive Science of Skin resources with this site.

We’re not standing still online. You will notice further changes in the coming months as they emerge from internal development and testing as well as new content being developed across the site.

Let us know your thoughts about our new site via Twitter, Facebook or email.

Bookmark and Share

Small populations, big therapeutic potential

Monday, May 23rd, 2011

When Andrew Pollack of the New York Times declared that the “world’s largest drug company is thinking small”, he wasn’t referring to reductions in sales force.

Rather, Pollack was reporting on a licensing deal between Pfizer and Israeli biotech company Protalix which built upon a growing global trend: big pharmaceutical companies were making a move into treatments for rare diseases, otherwise known as ‘orphan’ therapies.

In the months that followed Pollack’s December 2009 article, both Pfizer and GSK (two of the world’s largest pharmaceutical companies) launched specific business units focused on R&D for orphan drugs. In their announcements, both companies highlighted the significant unmet medical needs that exist in rare diseases and the potential of therapies that were in development. (more…)

Bookmark and Share

Summary of today’s announcements

Wednesday, July 14th, 2010

Today’s announcement of the results of CUV017 has brought with it a stream of updates from Clinuvel, on the website, YouTube and beyond.

In this post we summarise the days releases and developments.

(more…)

Bookmark and Share

Jack Wood discusses Clinuvel’s manufacturing partner for SCENESSE®

Friday, July 9th, 2010

Clinuvel Non-Executive Director Jack Wood discusses the selection of SurModics Inc as Clinuvel’s first commercial manufacturing partner for SCENESSE®. Click here to listen.

Bookmark and Share

Necessary innovation: the vital role of manufacturing in pharmaceutical development

Thursday, July 8th, 2010

This morning Clinuvel announced a significant milestone in its development program for SCENESSE®: the signing of the first manufacturing agreement for the final drug product with SurModics, Inc., a leading provider of drug delivery technologies to the healthcare industry. It has taken over eight years for Clinuvel to reach this milestone. In this time, the company has refined SCENESSE’s active ingredient – afamelanotide – and arrived at a final injectable drug product which controls its release to achieve an optimal photoprotective response in patients.

(more…)

Bookmark and Share

Broader implications of a landmark announcement

Monday, May 17th, 2010

I take a moment on this day to discuss a separate impact of the surprising development surrounding our photoprotective drug afamelanotide, despite this being a result where Clinuvel has not played any role other than making afamelanotide available to Italian patients.

Much as afamelanotide will assist and transform the lives of the population of Italian EPP patients, it also promises to evolve Clinuvel as a mature pharmaceutical company in Europe and the US.

(more…)

Bookmark and Share

Unexpected news for afamelanotide from Italy

Monday, May 17th, 2010

An unprecedented and unexpected announcement over the weekend has lead to the company’s announcement this morning that afamelanotide will be first made available to Italian erythropoietic protoporphyria (EPP) patients prior to its formal approval anywhere else in the world.

A governmental publication in Italy has confirmed that Clinuvel’s afamelanotide implant formulation can now be prescribed for patients diagnosed with EPP under Law 648/96, while marketing authorisation for the European Community is being prepared.

(more…)

Bookmark and Share

Clinuvel’s NewMedia Network

Tuesday, May 11th, 2010

Evolving our communications channels, digital in particular, was an obvious and necessary next step. The launch today has provided us with a dynamic and flexible new platform from which we can continue to innovate online.

Welcome to the new
www.clinuvel.com

(more…)

Bookmark and Share

Clinuvel’s digital media development

Monday, May 3rd, 2010

2010 is an important year for Clinuvel, as we progress afamelanotide in clinical trials across three continents.

A large part of our year is the refinement of our communications online. Feedback from many interested parties and stakeholders, and their constructive and excited responses have led us to develop digital communication opportunities and channels that: 
(more…)

Bookmark and Share

The Clinuvel technology series; in-depth discussion

Friday, February 5th, 2010

As part of a new series of updates on technology, and to complement on Clinuvel’s public news flow, Clinuvel is initiating a regular bulletin to provide its followers worldwide with the latest advances on relevant issues, such as environmental factors, skin and related biochemical issues.

These discussions aim to increase the understanding of the science and technology behind Clinuvel. Where the depth of information becomes too profound an attempt shall be made to summarise in easier terms. Basic take-aways will provide clarification throughout each bulletin.

The first issue, available here, discusses in detail the physiological “UV tanning response” and touches on the development of afamelanotide in relation to an evolving understanding of both the peptide itself and the physiology of UV and sun damage to skin and DNA.

Bookmark and Share